On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII
dc.contributor.author | Sørensen, B. | en_US |
dc.contributor.author | Dargaud, Y. | en_US |
dc.contributor.author | Kenet, G. | en_US |
dc.contributor.author | Lusher, Jeanne M. | en_US |
dc.contributor.author | Mumford, A. | en_US |
dc.contributor.author | Pipe, Steven W. | en_US |
dc.contributor.author | Tiede, A. | en_US |
dc.date.accessioned | 2012-03-16T15:53:01Z | |
dc.date.available | 2013-05-01T17:24:42Z | en_US |
dc.date.issued | 2012-03 | en_US |
dc.identifier.citation | Sørensen, B. ; Dargaud, Y. ; Kenet, G. ; Lusher, J. ; Mumford, A. ; Pipe, S. ; Tiede, A. (2012). "Onâ demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII." Haemophilia 18(2). <http://hdl.handle.net/2027.42/90042> | en_US |
dc.identifier.issn | 1351-8216 | en_US |
dc.identifier.issn | 1365-2516 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90042 | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Recombinant Activated Factor VII | en_US |
dc.subject.other | Haemophilia | en_US |
dc.subject.other | Inhibitor | en_US |
dc.subject.other | Treatment Strategies | en_US |
dc.title | On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Hannover Medical School, Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany | en_US |
dc.contributor.affiliationother | Haemostasis Research Unit, Centre for Haemostasis & Thrombosis, Guy’s & St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London, UK | en_US |
dc.contributor.affiliationother | Unité d’Hémostase Clinique, Hôpital Edouard Herriot, Lyon, France | en_US |
dc.contributor.affiliationother | National Hemophilia Center, Sheba Medical Center, Tel‐Hashomer, Israel | en_US |
dc.contributor.affiliationother | Department of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI, USA | en_US |
dc.contributor.affiliationother | Bristol Haemophilia Centre, Bristol Haematology and Oncology Centre, Bristol, UK | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90042/1/j.1365-2516.2011.02612.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2516.2011.02612.x | en_US |
dc.identifier.source | Haemophilia | en_US |
dc.identifier.citedreference | Tengborn L. Fibrinolytic Inhibitors in the Management of Bleeding Disorders. Canada: WFH publications, Treatment of Hemophilia; No. 42 (April 2007 ). | en_US |
dc.identifier.citedreference | Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high‐titre inhibitors. Haemophilia 2007; 13: 256 – 63. | en_US |
dc.identifier.citedreference | Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912 – 8. | en_US |
dc.identifier.citedreference | Kavakli K, Makris M, Zulfikar B et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi‐centre, randomised, double‐blind, cross‐over trial. Thromb Haemost 2006; 95: 600 – 5. | en_US |
dc.identifier.citedreference | Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367 – 71. | en_US |
dc.identifier.citedreference | Young G, Shafer FE, Rojas P, Seremetis S. Single 270 μg kg −1 ‐dose rFVIIa vs. standard 90 μg kg −1 ‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287 – 94. | en_US |
dc.identifier.citedreference | Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899 – 909. | en_US |
dc.identifier.citedreference | Croom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs 2008; 22: 121 – 36. | en_US |
dc.identifier.citedreference | Shapiro A. Inhibitor treatment: state of the art. Dis Mon 2003; 49: 22 – 38. | en_US |
dc.identifier.citedreference | Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546 – 51. | en_US |
dc.identifier.citedreference | Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7 – 10. | en_US |
dc.identifier.citedreference | Lusher JM. Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coagul Fibrinolysis 1998; 9 ( Suppl. 1 ): S111 – 4. | en_US |
dc.identifier.citedreference | Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11 ( Suppl. 1 ): S45 – 9. | en_US |
dc.identifier.citedreference | Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752 – 9. | en_US |
dc.identifier.citedreference | Abshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing. Semin Hematol 2004; 41 ( Suppl. 1 ): 3 – 7. | en_US |
dc.identifier.citedreference | Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22 – 6. | en_US |
dc.identifier.citedreference | Escobar MA. Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia 2010; 16 ( Suppl. 3 ): 29 – 34. | en_US |
dc.identifier.citedreference | Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven ® ) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352 – 9. | en_US |
dc.identifier.citedreference | Beyer R, Ingerslev J, Sorensen B. Muscle bleeds in professional athletes – diagnosis, classification, treatment and potential impact in patients with haemophilia. Haemophilia 2010; 16: 858 – 65. | en_US |
dc.identifier.citedreference | Beyer R, Ingerslev J, Sorensen B. Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia 2010; 16: 926 – 31. | en_US |
dc.identifier.citedreference | Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598 – 604. | en_US |
dc.identifier.citedreference | Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia 2010; 16 ( Suppl. 5 ): 85 – 92. | en_US |
dc.identifier.citedreference | Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002; 76 ( Suppl. 2 ): 139 – 44. | en_US |
dc.identifier.citedreference | Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747 – 57. | en_US |
dc.identifier.citedreference | Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898 – 902. | en_US |
dc.identifier.citedreference | Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638 – 48. | en_US |
dc.identifier.citedreference | Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437 – 42. | en_US |
dc.identifier.citedreference | Monroe DM. Further understanding of recombinant activated factor VII mode of action. Semin Hematol 2008; 45 ( Suppl. 1 ): S7 – 11. | en_US |
dc.identifier.citedreference | Ovanesov MV, Panteleev MA, Sinauridze EI et al. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis 2008; 19: 743 – 55. | en_US |
dc.identifier.citedreference | Pruthi RK, Schmidt KA, Slaby JA, Rodriguez V. Platelet dysfunction induced by herbal supplements in a patient with mild hemophilia A. J Thromb Haemost 2007; 5: 2556 – 8. | en_US |
dc.identifier.citedreference | DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 ( Suppl. 1 ): 1 – 22. | en_US |
dc.identifier.citedreference | Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134 – 46. | en_US |
dc.identifier.citedreference | Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12 ( Suppl. 6 ): 1 – 7. | en_US |
dc.identifier.citedreference | Gringeri A, Mannucci PM, Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611 – 9. | en_US |
dc.identifier.citedreference | Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 2000; 111: 78 – 90. | en_US |
dc.identifier.citedreference | Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591 – 605. | en_US |
dc.identifier.citedreference | Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006; 43 ( Suppl. 4 ): S8 – 13. | en_US |
dc.identifier.citedreference | Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia 2003; 9: 405 – 17. | en_US |
dc.identifier.citedreference | Perez Bianco R, Ozelo MC, Villaca PR et al. Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective. Medicina (B Aires) 2008; 68: 227 – 42. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.